Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
Saved in:
| Title: | Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. |
|---|---|
| Authors: | Budde LE; City of Hope National Medical Center, Duarte, California, United States., Kamdar M; Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, Colorado, United States., Assouline SE; Jewish General Hospital, McGill University, Canada., Chavez JC; Moffitt Cancer Center, Tampa, Florida, United States., Ghosh N; Levine Cancer Institute/Advocate Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States., Ollila TA; Brown University, Providence, Rhode Island, United States., Hodson DJ; Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Modi D; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States., Bastos-Oreiro M; Gregorio Marañón Hospital/Gregorio Marañón Research Institute, Madrid, Spain., Naik SG; Penn State University College of Medicine, Hershey, United States., Nakhoda SK; Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States., Batlevi CL MD, PhD; Genentech, Inc., South San Francisco, California, United States., Wang J; Genentech, Inc., South San Francisco, California, United States., Makadia S; Genentech, Inc., South San Francisco, California, United States., Kwan A; Genentech, Inc., South San Francisco, California, United States., Penuel E; Genentech, Inc., South San Francisco, California, United States., Jing J; Genentech, Inc., South San Francisco, California, United States., Wu H; Genentech, Inc., South San Francisco, California, United States., Ead W; Genentech, Inc., South San Francisco, California, United States., Pham S; Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada., To I; Genentech, Inc., South San Francisco, California, United States., Wei MC; Genentech, Inc., South San Francisco, California, United States., Wang M; University of Texas MD Anderson Cancer Center, Houston, Texas, United States. |
| Source: | Blood [Blood] 2026 Apr 21. Date of Electronic Publication: 2026 Apr 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
